Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperphosphatemia Clear all
Completed No phase listed Observational Results available

Long-term Effect of Lanthanum Carbonate on Bone

NCT00557323
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Lanthanum carbonate
Drug
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Lynwood, California • Torrance, California • Springfield, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

NCT00211939
View directory record Official record
Conditions
Calcinosis, Arteriosclerosis, Hyperparathyroidism, Secondary
Interventions
calcium acetate, sevelamer, atorvastatin
Drug
Lead sponsor
Nabi Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional

Phosphate Kinetic Modeling 2

NCT01252771
View directory record Official record
Conditions
Hyperphosphatemia, ESRD
Interventions
PKM Algorithm
Other
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis

NCT01191255
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Failure
Interventions
ferric citrate, ca acetate, sevelamer carbonate, placebo
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
52
States / cities
Tempe, Arizona • Los Angeles, California • Riverside, California + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional Results available

Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

NCT04046263
View directory record Official record
Conditions
Peritoneal Dialysis Complication, Hyperphosphatemia, Hypoalbuminemia
Interventions
Sucroferric Oxyhydroxide Chewable Tablet
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

NCT00772382
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis, Hyperphosphatemia
Interventions
MCI-196
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Tarzana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 9:34 PM EDT
Withdrawn No phase listed Observational

Calcium, Phosphate, Renal Impairment and Coronary Artery Disease in the Cardio-renal Syndrome, The CAPRICORN-CRS Study

NCT00853541
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 3 Interventional

Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

NCT02492620
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperphosphatemia, Iron Deficiency Anemia, Renal Insufficiency
Interventions
Ferric Citrate
Drug
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 1 Interventional

Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphatemia

NCT01057108
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease
Interventions
FOSTRAP Chewing Gum, Placebo chewing gum
Other
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 6, 2011 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

NCT05085275
View directory record Official record
Conditions
Anemia, Iron Deficiency, Hyperphosphatemia, Renal Insufficiency, Chronic, Renal Anemia, Disease Progression, Cardiovascular, Iron
Interventions
Ferric Citrate 1 GM Oral Tablet [AURYXIA], Placebo
Drug
Lead sponsor
USRC Kidney Research
Network
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
23
States / cities
Pine Bluff, Arkansas • Chula Vista, California • El Centro, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients

NCT00660530
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Disease
Interventions
Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Not applicable Interventional

PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum

NCT01319578
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease
Interventions
K2CG chewing gum
Other
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 14, 2011 · Synced Jul 22, 2026, 9:34 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
48
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 1 Interventional

A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

NCT02965053
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
EOS789, Placebo, Renvela
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients

NCT01464190
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
PA21 (2.5 g tablet containing 500 mg iron), Sevelamer carbonate
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
659 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional Results available

Phosphate Lowering in CKD Trial

NCT02209636
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Lanthanum carbonate, placebo, Ascorbic Acid, Nitroglycerin, Flow-mediated dilation measurement, Aortic pulse-wave velocity, Endothelial cell collection
Drug · Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 79 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Jul 22, 2026, 9:34 PM EDT
Not listed Phase 2 Interventional

Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia

NCT00358046
View directory record Official record
Conditions
Kidney Diseases, Renal Insufficiency
Interventions
ILY101
Drug
Lead sponsor
Ilypsa
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Mobile, Alabama • Mountain View, California • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2007 · Synced Jul 22, 2026, 9:34 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

NCT06712654
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
Interventions
AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID, AP306 75 mg TID, AP306 100 mg TID, AP306 125 mg TID, Placebo
Drug
Lead sponsor
R1 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Huntsville, Alabama • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional Results available

Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients

NCT03079869
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Ferric Citrate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Not applicable Interventional Results available

The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease

NCT01002872
View directory record Official record
Conditions
Metabolic Bone Disease
Interventions
Lanthanum Carbonate (Fosrenol), placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional Results available

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

NCT03988920
View directory record Official record
Conditions
Hyperphosphatemia, End Stage Renal Disease
Interventions
Tenapanor, Sevelamer Carbonate
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
Not listed
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

NCT01574326
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease
Interventions
Placebo, Sevelamer carbonate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 18 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 1Phase 2 Interventional

The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients

NCT00508885
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Niacinamide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
17 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2007 · Synced Jul 22, 2026, 9:34 PM EDT
Completed Phase 4 Interventional

Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants

NCT04922645
View directory record Official record
Conditions
Hyperphosphatemia, Anemia, Iron Deficiency, Renal Insufficiency
Interventions
Ferric Citrate 1 gram Oral Tablet, Standard of care phosphate-lowering therapy
Drug
Lead sponsor
USRC Kidney Research
Network
Eligibility
18 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Anchorage, Alaska • Mesa, Arizona • Pine Bluff, Arkansas + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Jul 22, 2026, 9:34 PM EDT